Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (NYSE: ABBV) received U.S. FDA approval for DECNUPAZ (pivekimab sunirine-pvzy) to treat adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer with limited options.
The approval is based on the Phase 1/2 CADENZA trial, where newly diagnosed BPDCN patients (n=33) had a 69.7% composite complete response with 9.7‑month median duration; relapsed/refractory patients (n=51) showed a 15.7% composite complete response with 9.2‑month median duration. DECNUPAZ is the first and only CD123‑targeting antibody‑drug conjugate that can be initiated in an outpatient setting and is AbbVie’s first ADC approved for blood cancer. Common adverse reactions (≥20%) included edema, fatigue, musculoskeletal pain, hemorrhage, infusion‑related reactions, nausea, and diarrhea, and the drug carries a boxed warning for hepatotoxicity, including hepatic veno‑occlusive disease.
AbbVie (NYSE: ABBV) announced a positive CHMP opinion recommending approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C in adults and children ≥3 years in the EU. The opinion is based on Phase 3 M20-350 data showing a 96% cure rate (SVR12) over eight weeks, with a safety profile generally consistent with prior experience. A final European Commission decision is expected in Q3 2026, which would expand MAVIRET’s indication to both acute and chronic HCV.
AbbVie (NYSE: ABBV) will present extensive oncology pipeline data at the ASCO 2026 Annual Meeting, covering solid tumors and blood cancers.
Highlights include Phase 1 Top1i ADC results in mCRPC, SCLC, PROC and HNSCC, and Phase 1b T‑cell engager data in relapsed/refractory multiple myeloma showing notable objective response rates and manageable safety profiles.
Allergan Aesthetics (NYSE: ABBV) received a positive CHMP opinion for Boey (trenibotulinumtoxinE) to temporarily improve moderate to severe glabellar lines in adults in 30 EU/EEA markets. Recommendations follow two Phase 3 trials meeting all endpoints, showing onset from 8 hours and 2–3 weeks’ efficacy, with adverse events similar to placebo.
AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on May 13, 2026, with management appearing in a fireside chat at 1:20 p.m. Central Time. A live audio webcast will stream on AbbVie’s Investor Relations website, with an archive available later that day.
AbbVie (NYSE: ABBV) reported 18 abstracts at DDW 2026 highlighting real-world and clinical long-term data for risankizumab and upadacitinib in Crohn's disease and ulcerative colitis. Results include sustained symptom and endoscopic improvements, reduced corticosteroid use, quality-of-life gains, lower switch rates, and lower hospitalization odds.
NImmune Biopharma (NYSE:ABBV) presented Phase 1 and preclinical data at Digestive Disease Week 2026 showing that oral, once-daily NIM-1324 met primary and secondary endpoints, engaged the LANCL2 target, showed improved PK, and had a favorable safety profile with no dose-limiting toxicities.
The program advances a LANCL2 immunometabolic mechanism for ulcerative colitis and Crohn’s disease and supports a well-powered Phase 2 testing 125, 250, and 1000 mg doses versus placebo.
Allergan Aesthetics (NYSE: ABBV) announced a charitable initiative for Skin Cancer Awareness Month on April 30, 2026. Throughout May, Allē will donate $10 for every new member who joins via referral, capped at $100,000. New referred members get $50 off their first treatment; referrers receive $10 off their next treatment. Referrals must be made through the Allē app and qualifying treatment and purchase must occur within 60 days of registration. Terms limit five referral offers per member per calendar year.
AbbVie (NYSE:ABBV) reported Q1 2026 net revenues of $15.002B, up 12.4% reported (10.3% operational). GAAP diluted EPS was $0.39; adjusted diluted EPS was $2.65, which includes an unfavorable $0.41 per-share impact from acquired IPR&D and milestones. AbbVie raised 2026 adjusted EPS guidance to $14.08–$14.28 (includes the $0.41 impact year-to-date).
Key portfolio highlights: Skyrizi $4.483B, Rinvoq $2.119B, Humira $688M; neuroscience $2.875B; oncology $1.631B; aesthetics $1.186B. Major items include FDA approval for Venclexta+acalabrutinib in frontline CLL, FDA CRL for trenibotE manufacturing, regulatory submissions for Skyrizi CD and Rinvoq alopecia areata, and multi-site manufacturing investments totaling $1.78B.
AbbVie (NYSE: ABBV) submitted an FDA application for upadacitinib (RINVOQ) 15 mg and 30 mg once daily for adults and adolescents with severe alopecia areata, based on Phase 3 UP-AA data.
In two replicate trials (N=1,399), the primary endpoint SALT ≤ 20 at week 24 was met for both doses; response rates improved through week 52. Safety through week 52 was described as consistent with earlier results. Use in AA is not approved and remains under regulatory review.